<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Platelets</journal-id><journal-id journal-id-type="iso-abbrev">Platelets</journal-id><journal-id journal-id-type="publisher-id">PLT</journal-id><journal-title-group><journal-title>Platelets</journal-title></journal-title-group><issn pub-type="ppub">0953-7104</issn><issn pub-type="epub">1369-1635</issn><publisher><publisher-name>Informa UK Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23249161</article-id><article-id pub-id-type="pmc">3809924</article-id><article-id pub-id-type="doi">10.3109/09537104.2012.748185</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers</article-title></title-group><contrib-group><contrib id="a1" contrib-type="author"><name><surname>Teng</surname><given-names>Renli</given-names></name><xref ref-type="aff" rid="end-a1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cn1">
<sup>*</sup>
</xref></contrib><contrib id="a2" contrib-type="author"><name><surname>Maya</surname><given-names>Juan</given-names></name><xref ref-type="aff" rid="end-a1">
<sup>1</sup>
</xref></contrib><contrib id="a3" contrib-type="author"><name><surname>Butler</surname><given-names>Kathleen</given-names></name><xref ref-type="aff" rid="end-a1">
<sup>1</sup>
</xref></contrib><aff id="end-a1"><sup>1</sup><institution>AstraZeneca LP</institution>, <addr-line>Wilmington, DE</addr-line>, <country>USA</country></aff></contrib-group><author-notes><corresp id="cn1"><sup>*</sup><italic>Correspondence</italic>: <addr-line>R. Teng</addr-line>, <institution>Department of Clinical Pharmacology</institution>, <addr-line>AstraZeneca LP, FOC W1-677, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437</addr-line>, <country>USA</country>. <phone>+1 303 885 5435</phone>. <fax>+1 302 885 9472</fax>. <email xlink:href="renli.teng@astrazeneca.com">renli.teng@astrazeneca.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>18</day><month>12</month><year>2012</year></pub-date><volume>24</volume><issue>8</issue><fpage>615</fpage><lpage>624</lpage><history><date date-type="received"><day>20</day><month>7</month><year>2012</year></date><date date-type="rev-recd"><day>2</day><month>11</month><year>2012</year></date><date date-type="accepted"><day>6</day><month>11</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; 2013 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted</copyright-statement><copyright-year>2013</copyright-year></permissions><abstract><p>The results of two independent, randomized, two-period crossover, single-center studies, conducted to assess the pharmacokinetics of ticagrelor&#x02009;&#x000b1;&#x02009;aspirin, inhibition of platelet aggregation (IPA) with ticagrelor/aspirin vs. clopidogrel/aspirin, and safety, tolerability, and bleeding times are reported here. In Study A (open-label), 16 volunteers received ticagrelor (50&#x02009;mg bid Days 1&#x02013;5; 200&#x02009;mg bid Days 6&#x02013;9; one 200&#x02009;mg dose on Day 10)&#x02009;&#x000b1;&#x02009;300&#x02009;mg qd aspirin (Days 1&#x02013;10). In Study B (double-blind, double-dummy), 16 volunteers received aspirin (300&#x02009;mg loading dose/75&#x02009;mg qd Days 2&#x02013;9) with either ticagrelor (200&#x02009;mg bid Days 4&#x02013;8, one 200&#x02009;mg dose on Day 9) or clopidogrel (300&#x02009;mg loading dose Day 4, 75&#x02009;mg qd Days 5&#x02013;9). At steady-state ticagrelor (50&#x02009;mg bid, or 200&#x02009;mg bid), concomitant aspirin (300&#x02009;mg qd) had no effect on mean maximum plasma concentration (<italic>C</italic>
<sub>max</sub>), median time to <italic>C</italic>
<sub>max</sub> (<italic>t</italic>
<sub>max</sub>), or mean area under the plasma concentration-time curve for the dosing interval (AUC<sub>0&#x02013;</sub>
<italic><sub>&#x003c4;</sub></italic>) for ticagrelor and its primary metabolite, AR-C124910XX. Following 200&#x02009;mg bid ticagrelor, mean <italic>C</italic>
<sub>max</sub> and AUC<sub>0&#x02013;</sub>
<italic><sub>&#x003c4;</sub></italic> for both parent and metabolite were comparable with co-administration of aspirin at 75&#x02009;mg and 300&#x02009;mg qd. Aspirin (300&#x02009;mg qd) had no effect on IPA (ADP-induced) by ticagrelor. However, aspirin and ticagrelor had an additive effect on IPA (collagen-induced). Ticagrelor/aspirin increased bleeding times vs. baseline. Ticagrelor/aspirin co-administration was well tolerated at all dose combinations evaluated. In summary, the findings of this study demonstrate that co-administration of aspirin (300&#x02009;mg qd) with ticagrelor (50&#x02009;mg bid, or 200&#x02009;mg bid) had no effect on ticagrelor pharmacokinetics or IPA (ADP-induced) by ticagrelor.</p></abstract><kwd-group kwd-group-type="author"><kwd>Ticagrelor</kwd><kwd>P2Y<sub>12</sub> receptor antagonist</kwd><kwd>antiplatelet therapy</kwd><kwd>aspirin</kwd><kwd>clopidogrel</kwd><kwd>pharmacokinetics</kwd></kwd-group></article-meta></front><body><sec id="ss1"><title>Introduction</title><p>Ticagrelor is a direct-acting, reversibly binding, oral P2Y<sub>12</sub> receptor antagonist <xref ref-type="bibr" rid="b1">[1]</xref>. In patients with acute coronary syndromes (ACS), the Phase III PLATelet inhibition and patient Outcomes (PLATO) trial demonstrated that ticagrelor plus aspirin significantly reduced the primary composite endpoint of myocardial infarction (MI)/stroke/death from vascular causes vs. clopidogrel plus aspirin, without increasing PLATO-defined major bleeding <xref ref-type="bibr" rid="b2">[2]</xref>. Ticagrelor is approved in more than 70 countries for the prevention of atherothrombotic events in adult ACS patients <xref ref-type="bibr" rid="b3">[3]</xref>, <xref ref-type="bibr" rid="b4">[4]</xref>. Updated guidelines recommend ticagrelor co-administered with low-dose aspirin as a dual antiplatelet therapy for the management of any ACS patient <xref ref-type="bibr" rid="b5">[5]</xref> and those with non-ST-segment elevation <xref ref-type="bibr" rid="b6">[6]</xref>. Ticagrelor is also recommended as an oral antiplatelet therapy in percutaneous coronary intervention <xref ref-type="bibr" rid="b7">[7]</xref>.</p><p>Ticagrelor underwent an extensive development program which included early pharmacokinetic and pharmacodynamic studies. Ticagrelor has a major metabolite, AR-C124910XX <xref ref-type="bibr" rid="b8">[8]</xref>, which is approximately equipotent to ticagrelor in blocking ADP-induced platelet aggregation (AstraZeneca, data on file). Rapid onset of inhibition of platelet aggregation (IPA) is achieved with ticagrelor, and IPA then declines from 12 hours post-dosing <xref ref-type="bibr" rid="b9">[9]</xref>. Ticagrelor plus aspirin showed more rapid, greater and more consistent IPA vs. clopidogrel plus aspirin in patients with ACS <xref ref-type="bibr" rid="b10">[10]</xref> or atherosclerosis <xref ref-type="bibr" rid="b11">[11]</xref>.</p><p>Dual antiplatelet therapy involving aspirin is a key strategy for managing ACS <xref ref-type="bibr" rid="b6">[6]</xref>. By irreversibly inhibiting cyclooxygenase, aspirin blocks arachidonic-acid induced platelet aggregation <xref ref-type="bibr" rid="b12">[12]</xref>. A single, oral 100&#x02009;mg aspirin dose is sufficient to completely block the cyclooxygenase activity <xref ref-type="bibr" rid="b13">[13]</xref>. However, a wide range (50&#x02013;1500&#x02009;mg once daily [qd]) of aspirin doses has been used in clinical trials <xref ref-type="bibr" rid="b14 b15 b16">[14&#x02013;16]</xref>. Also, several analyses have reported that aspirin efficacy (i.e. prevention of serious vascular events) is not dose-related, and the highest efficacy is seen with 75&#x02013;150&#x02009;mg qd <xref ref-type="bibr" rid="b14">[14]</xref>, <xref ref-type="bibr" rid="b17">[17]</xref>. In contrast, bleeding events increase with increasing aspirin dose <xref ref-type="bibr" rid="b18">[18]</xref>.</p><p>Aspirin dose has also been shown to influence the efficacy of ticagrelor. A <italic>post-hoc</italic> subgroup analysis of the PLATO trial showed a significant interaction (<italic>p</italic>&#x02009;=&#x02009;0.00006) between aspirin dose category and treatment. In patients taking&#x02009;&#x02264;100&#x02009;mg maintenance aspirin, ticagrelor was associated with a reduction in the rate of MI, stroke and death from vascular causes, compared with clopidogrel (adjusted hazard ratio [HR] 0.77 [95% confidence interval (CI), 0.69&#x02013;0.86]). However, in patients taking a maintenance aspirin dose &#x02265;300&#x02009;mg, the HR of 1.45 (95% CI, 1.01&#x02013;2.09) favored clopidogrel <xref ref-type="bibr" rid="b19">[19]</xref>.</p><p>Given the key role of aspirin in ACS therapies, two healthy volunteer studies were conducted early in the ticagrelor development program to explore the potential effect of aspirin on the pharmacokinetics and pharmacodynamics of ticagrelor. Two aspirin doses were assessed in these previously unpublished trials: 75&#x02009;mg qd (in the effective dose range for thromboembolic event reduction <xref ref-type="bibr" rid="b14">[14]</xref>) and 300&#x02009;mg qd (close to 325&#x02009;mg qd commonly used in the USA <xref ref-type="bibr" rid="b17">[17]</xref>). The primary objectives of these studies were to evaluate ticagrelor pharmacokinetics with and without aspirin (D5130C0005; Study A), and to compare IPA with ticagrelor plus aspirin vs. clopidogrel plus aspirin (D5130C05261; Study B). Key secondary objectives included the assessment of the safety and tolerability of ticagrelor with or without aspirin, and bleeding times.</p><p>The data presented in these studies provide information important to the understanding of pharmacokinetic and pharmacodynamic aspects of any potential interaction between ticagrelor and aspirin maintenance dose.</p></sec><sec sec-type="methods" id="ss2"><title>Methods</title><sec id="ss3"><title>Study populations</title><sec id="ss4"><title>Sample size</title><p>Sixteen randomized, healthy volunteers were planned for Study A to achieve at least 12 evaluable subjects, which would give at least 80% power (5% significance level) to show that the 90% CIs for differences between ticagrelor/aspirin and ticagrelor were within 70&#x02013;143%, if the hypothesis of equality was true.</p><p>For study B, a non-parametric calculation (at least 90% power, 5% significance level) showed that at least 12 healthy volunteers were required if the probability of a higher IPA in the ticagrelor/aspirin group vs. the clopidogrel/aspirin group was to be 90%.</p></sec><sec id="ss5"><title>Inclusion/exclusion criteria</title><p>For both studies, key inclusion criteria were: males or females (post-menopausal or surgically sterile); 18&#x02013;65 years; body mass index (BMI) 18&#x02013;30&#x02009;kg/m<sup>2</sup>. Key exclusion criteria were: presence or history of conditions affecting drug disposition; any clinically significant electrocardiogram (ECG) findings, laboratory or coagulation abnormalities; a history of alcohol or substance abuse.</p></sec><sec id="ss6"><title>Ethics</title><p>Written, informed consent was provided by all volunteers in both studies. An Independent Ethics Committee for each study approved the final protocol and amendments. The studies were performed in accordance with Declaration of Helsinki principles, and were consistent with ICH/Good Clinical Practice, applicable regulatory guidelines and AstraZeneca bioethics policy.</p></sec></sec><sec id="ss7"><title>Study designs and treatment</title><p>Study A was a randomized, open-label, two-period crossover, single center study (<xref ref-type="fig" rid="F1">Figure 1a</xref>). Enrolment and screening took place up to 21 days prior to admission. Eligibility was confirmed on admission (Day &#x02013;1) and on study Day 1 volunteers were randomized to one of the two treatment sequences (AB or BA). Volunteers (<italic>N</italic>&#x02009;=&#x02009;16) received ticagrelor 50&#x02009;mg (twice daily) bid Days 1&#x02013;5, 200&#x02009;mg bid Days 6&#x02013;9, and a single 200&#x02009;mg dose on Day 10 without aspirin (Treatment A in Study A) and with aspirin 300&#x02009;mg qd Days 1&#x02013;10 (Treatment B in Study A). The dosing schedule and details are shown in <xref ref-type="fig" rid="F1">Figure 1(a)</xref>. Caffeine-containing products, alcohol, over-the-counter preparations, and non-steroidal anti-inflammatory drugs were not permitted from prior to admission until discharge after each period.<fig fig-type="fig" id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Designs for Study A and Study B.</p></caption><graphic xlink:href="PLA-24-615-g001"/></fig>
</p><p>Study B was a randomized, double-blind, double-dummy, two-treatment, two-period crossover, single center study (<xref ref-type="fig" rid="F1">Figure 1b</xref>). Enrolment and screening took place up to 21 days prior to admission. Eligibility was confirmed on admission (Day &#x02013;2), and on study Day 1 volunteers were randomized to one of two treatment sequences (AB or BA). Volunteers (<italic>N</italic>&#x02009;=&#x02009;16) received ticagrelor at 200&#x02009;mg bid on Days 4&#x02013;8 and in the morning only on Day 9 (Treatment A in Study B), and clopidogrel at a 300&#x02009;mg loading dose on Day 4, then 75&#x02009;mg qd Days 5&#x02013;9 (Treatment B in Study B). For both treatments A and B, aspirin was administered on Day 1 (300&#x02009;mg), and on Days 2&#x02013;9 75&#x02009;mg qd. The dosing schedule and details are shown in <xref ref-type="fig" rid="F1">Figure 1(b)</xref>. This study used the early tablet formulation of ticagrelor; 100 mg bid was demonstrated to provide comparable exposure to that of 90&#x02009;mg bid of the commercially-available tablet formulation. Restrictions during the study were as for Study A.</p></sec><sec id="ss8"><title>Ticagrelor pharmacokinetic sample collection</title><p>Venous blood samples (2&#x02009;ml) were collected into lithium-heparin tubes. Plasma samples were prepared by centrifugation (1500&#x02009;<italic>g</italic>, 10 minutes, 4&#x000b0;C) within 30 minutes, and stored frozen (&#x02212;20&#x000b0;C) until analyzed.</p><p>For Study A, sampling times were: pre-dose on Days 1, 4, and 9; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours post-morning dose on Days 5 (ticagrelor 50&#x02009;mg bid) and 10 (ticagrelor 200&#x02009;mg bid), and 18, 24, 36, 48, and 72 hours post-morning dose on Day 10. Sampling times for Study B following multiple doses of ticagrelor/aspirin and clopidogrel/aspirin were 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, and 24 hours post-morning dose on the final day of dosing (Day 9).</p></sec><sec id="ss9"><title>Analysis of ticagrelor and AR-C124910XX</title><p>Ticagrelor and AR-C124910XX plasma concentrations were analyzed, after protein precipitation, using a fully validated liquid chromatography with the tandem mass spectrometry method <xref ref-type="bibr" rid="b20">[20]</xref>. Lower limits of quantification were 5&#x02009;ng/ml (ticagrelor) and 2.5&#x02009;ng/ml (AR-C124910XX).</p></sec><sec id="ss10"><title>Assessment of platelet aggregation inhibition</title><p>Blood sampling times in Study A for both study periods were: Day 1 pre-dose (baseline), and 2 hours post-aspirin dose on Day 1 (Treatment B only); 0 (pre-dose), 4, 8, 12 hours post-morning dose on Day 5; 0 (pre-dose), 2, 4, 8, 12, 24, and 36 hours post-morning dose on Day 10. For Study B, sampling times were: pre-dose on Day 1 (baseline); 2 hours post-aspirin dose on Day 3; 0 (pre-dose) on Day 4; 0 (pre-dose), 2, 4, 12, and 24 hours post-morning dose on Day 9.</p><p>Venous blood samples (4.5&#x02009;ml) were collected into tubes containing 0.5&#x02009;ml of 3.8% sodium citrate. Samples were centrifuged (180&#x02013;200&#x02009;<italic>g</italic>, 10 minutes, room temperature). The platelet count of the resulting platelet-rich plasma was adjusted to 300&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/l using autologous platelet-poor plasma. Agonists for platelet aggregation were 20&#x02009;&#x000b5;M ADP, or 4&#x02009;&#x000b5;g/ml collagen. Final-extent IPA was assessed by optical aggregometry as described previously <xref ref-type="bibr" rid="b21">[21]</xref>.</p></sec><sec id="ss11"><title>Evaluation of bleeding times</title><sec id="ss12"><title>Simplate method</title><p>Bleeding times in Study A for both study periods were: Day 1 pre-dose; 4 and 24 hours post-morning dose on Days 4 and 9. A distending venous pressure (40&#x02009;mmHg) was applied with a standard sphygmomanometer cuff for 30&#x02013;60 seconds before and throughout the procedure. A Simplate&#x000ae; device was used to make one incision (1&#x02009;mm depth by 5&#x02009;mm long) on the forearm. The incision was blotted every 30 seconds until bleeding ceased, and the time recorded to the nearest 15 seconds.</p></sec><sec id="ss13"><title>Lancet method</title><p>In Study A, lancet bleeding times were measured at enrolment, and at 4&#x000a0;hours post-dosing on Day 9 of both periods. For Study B, bleeding times were assessed at screening (baseline): 4 hours post-aspirin dose on Day 3, pre-dose on Day 4, pre-dose and 4 hours post-dose on Day 9 of both study periods.</p><p>A distending venous pressure (40&#x02009;mmHg) was applied with a standard sphygmomanometer cuff for 30 seconds before and throughout the procedure. Using a standard lancet (Styrex 3&#x02009;mm depth by 1&#x02009;mm wide [Study A]; BD Genie Safety Lancet, 2&#x02009;mm depth by 1.5&#x02009;mm width [Study B]), two evenly spaced punctures on the circumference of a 20&#x02009;mm diameter circle were made rapidly into the volar surface of the forearm away from superficial veins. Blood was blotted from the punctures every 15 seconds (Study B) or 30 seconds (Study A) until bleeding ceased, and the time to the nearest 15 seconds was recorded <xref ref-type="bibr" rid="b22">[22]</xref>.</p></sec></sec><sec id="ss14"><title>Safety and tolerability</title><p>Safety was evaluated by monitoring adverse events (AEs), laboratory parameters, vital signs, ECGs, physical examination at various times throughout the treatment periods and at the follow-up visit.</p></sec><sec id="ss15"><title>Data analyses</title><sec id="ss16"><title>Pharmacokinetic analyses</title><p>Pharmacokinetic parameters were estimated by standard non-compartmental methods using WinNonlin Professional (Pharsight Corporation, Mountain View, California). Maximum concentration (<italic>C</italic>
<sub>max</sub>), time to <italic>C</italic>
<sub>max</sub> (<italic>t</italic>
<sub>max</sub>), and area under the plasma concentration-time curve for the dosing interval (AUC<sub>0&#x02013;</sub>
<italic><sub>&#x003c4;</sub></italic>) were calculated for ticagrelor and AR-C124910XX.</p></sec><sec id="ss17"><title>Pharmacodynamic analyses</title><p>IPA (%) was calculated by 100&#x02009;&#x000d7;&#x02009;(PA<sub>BL</sub>&#x02013;PA<sub>T</sub>)/PA<sub>BL</sub>; PA<sub>BL</sub>&#x02009;=&#x02009;mean pre-dose baseline response, PA<sub>T</sub>&#x02009;=&#x02009;mean platelet aggregation response at time T. For Study B, individual peak IPA (IPA<sub>max</sub>) was the highest observed IPA following ticagrelor or clopidogrel administration, and time to IPA<sub>max</sub> (TIPA<sub>max</sub>) was evaluated. Values for area under the effect curve (AUEC) of IPA from 0 to 12 hours (AUEC<sub>0&#x02013;12</sub>) and from 0 to 24 hours (AUEC<sub>0&#x02013;24</sub>) were calculated from IPA-time curves, using the linear trapezoidal rule.</p></sec><sec id="ss18"><title>Statistical analyses</title><p>Statistical analyses were performed using SAS Version 8.12 (SAS Institute, Cary, North Carolina, USA). Pharmacokinetic data were descriptively summarized. Plasma concentration-time curves were plotted. In Study A, for the pharmacokinetic parameters, <italic>C</italic>
<sub>max</sub> and AUC<sub>0&#x02013;</sub>
<italic><sub>&#x003c4;</sub></italic>, 90% CIs were calculated for the differences between ticagrelor/aspirin and ticagrelor alone. After log-transformation, these data were analyzed by the analysis of variance (ANOVA) fitting a fixed-effect term for volunteers. Least square (LS) mean ratio point estimates and two-sided 90% CIs for ticagrelor/aspirin:ticagrelor ratio were exponentially back-transformed to present the point estimates and CIs in the original linear scale.</p><p>In Study B, mean IPA-time curves were plotted. AUEC<sub>0&#x02013;12</sub>, AUEC<sub>0&#x02013;24</sub>, and IPA<sub>max</sub> data were analyzed by ANOVA, fitting fixed-effect terms for sequence, volunteer within sequence, period, and treatment. Point estimates and corresponding 95% CIs were estimated for the difference between ticagrelor/aspirin and clopidogrel/aspirin groups.</p></sec></sec></sec><sec sec-type="results" id="ss19"><title>Results</title><sec id="ss20"><title>Demographic and baseline characteristics</title><p>In Study A, of the 16 randomized volunteers, 14 (88%) were male, 15 were Caucasian, and one was Black. The mean (range) age and body weight were 37 (21&#x02013;54) years and 73 (53&#x02013;108) kg, respectively. Three volunteers discontinued due to AEs.</p><p>In Study B, 15/16 (94%) volunteers were male, 15 were Caucasian, and one was Oriental. The mean (range) age and body weight were 35 (18&#x02013;53) years and 72 (55&#x02013;97) kg, respectively. All volunteers completed this study.</p></sec><sec id="ss21"><title>Effect of aspirin on ticagrelor pharmacokinetic parameters</title><p>In Study A, following the administration of ticagrelor alone, ticagrelor was rapidly absorbed (<xref ref-type="fig" rid="F2">Figure 2a</xref>) with a median <italic>t</italic>
<sub>max</sub> of 3 hours, and AR-C124910XX was rapidly formed (<xref ref-type="fig" rid="F2">Figure 2b</xref>) with a similar median <italic>t</italic>
<sub>max</sub> (3 hours; <xref ref-type="table" rid="T1">Table I</xref>). Mean <italic>C</italic>
<sub>max</sub> and AUC<sub>0&#x02013;</sub>
<italic><sub>&#x003c4;</sub></italic> for AR-C124910XX were approximately one-third of ticagrelor values at both ticagrelor doses (<xref ref-type="table" rid="T1">Table I</xref>).<fig fig-type="fig" id="F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Plasma concentration profiles of (a) ticagrelor and (b) AR-C124910XX following administration of ticagrelor (50&#x02009;mg bid for 5 days, or 200&#x02009;mg bid for 4 days then qd for 1&#x02009;day)&#x02009;&#x000b1;&#x02009;once-daily aspirin (300&#x02009;mg) (Study A). Values are mean&#x02009;&#x000b1;&#x02009;SD, <italic>n</italic>&#x02009;=&#x02009;13 at each time point.</p></caption><graphic xlink:href="PLA-24-615-g002"/></fig>
</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table I.&#x02003;</label><caption><p>Steady state pharmacokinetic parameters of ticagrelor and AR-C124910XX following the administration of ticagrelor&#x02009;&#x000b1;&#x02009;once-daily aspirin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="6" rowspan="1">Study A<hr/>
</th><th align="center" rowspan="1" colspan="1">Study B</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">Ticagrelor 50&#x02009;mg bid<xref ref-type="fn" rid="T1-F1"><sup>a</sup></xref>
<hr/>
</th><th align="center" colspan="3" rowspan="1">Ticagrelor 200&#x02009;mg bid<xref ref-type="fn" rid="T1-F2"><sup>b</sup></xref>
<hr/>
</th><th align="center" rowspan="1" colspan="1">Ticagrelor 200&#x02009;mg bid<xref ref-type="fn" rid="T1-F3"><sup>c</sup></xref>
</th></tr><tr><th align="left" rowspan="1" colspan="1"> Parameter</th><th align="center" rowspan="1" colspan="1">Ticagrelor alone (<italic>n</italic>&#x02009;=&#x02009;13)</th><th align="center" rowspan="1" colspan="1">Ticagrelor&#x02009;+&#x02009;aspirin 300&#x02009;mg qd (<italic>n</italic>&#x02009;=&#x02009;13)</th><th align="center" rowspan="1" colspan="1">LS means ratio % (90% CI)</th><th align="center" rowspan="1" colspan="1">Ticagrelor alone (<italic>n</italic>&#x02009;=&#x02009;13)</th><th align="center" rowspan="1" colspan="1">Ticagrelor&#x02009;+&#x02009;aspirin 300&#x02009;mg qd (<italic>n</italic>&#x02009;=&#x02009;13)</th><th align="center" rowspan="1" colspan="1">LS means ratio % (90% CI)</th><th align="center" rowspan="1" colspan="1">Ticagrelor&#x02009;+&#x02009;aspirin 75&#x02009;mg qd (<italic>n</italic>&#x02009;=&#x02009;16)</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">
<bold>Ticagrelor</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>C</italic>
<sub>max</sub> (ng/ml)</td><td char="(" rowspan="1" colspan="1">353 (41)</td><td char="(" rowspan="1" colspan="1">334 (32)</td><td char="(" rowspan="1" colspan="1">96 (80&#x02013;115)</td><td char="(" rowspan="1" colspan="1">1777 (48)</td><td char="(" rowspan="1" colspan="1">1697 (47)</td><td char="(" rowspan="1" colspan="1">96 (80&#x02013;116)</td><td char="(" rowspan="1" colspan="1">1478 (37)</td></tr><tr><td rowspan="1" colspan="1">AUC<sub>0&#x02013;</sub>
<italic><sub>&#x003c4;</sub></italic> (ng&#x000b7;h/ml)</td><td char="(" rowspan="1" colspan="1">2218 (36)</td><td char="(" rowspan="1" colspan="1">2193 (38)</td><td char="(" rowspan="1" colspan="1">99 (86&#x02013;114)</td><td char="(" rowspan="1" colspan="1">12 026 (60)</td><td char="(" rowspan="1" colspan="1">11 576 (54)</td><td char="(" rowspan="1" colspan="1">97 (84&#x02013;111)</td><td char="(" rowspan="1" colspan="1">10 391 (33)</td></tr><tr><td rowspan="1" colspan="1">
<italic>t</italic>
<sub>max</sub> (h)</td><td char="(" rowspan="1" colspan="1">3.0 (2.0&#x02013;4.0)</td><td char="(" rowspan="1" colspan="1">3.0 (1.0&#x02013;6.0)</td><td rowspan="1" colspan="1">NA</td><td char="(" rowspan="1" colspan="1">3.0 (1.0&#x02013;4.0)</td><td char="(" rowspan="1" colspan="1">3.0 (2.0&#x02013;6.0)</td><td rowspan="1" colspan="1">NA</td><td char="(" rowspan="1" colspan="1">3.1 (1.1&#x02013;4.2)</td></tr><tr><td rowspan="1" colspan="1">
<bold>AR-C124910XX</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>C</italic>
<sub>max</sub> (ng/ml)</td><td char="(" rowspan="1" colspan="1">92 (40)</td><td char="(" rowspan="1" colspan="1">97 (25)</td><td char="(" rowspan="1" colspan="1">106 (92&#x02013;122)</td><td char="(" rowspan="1" colspan="1">490 (20)</td><td char="(" rowspan="1" colspan="1">495 (29)</td><td char="(" rowspan="1" colspan="1">102 (88&#x02013;117)</td><td char="(" rowspan="1" colspan="1">501 (27)</td></tr><tr><td rowspan="1" colspan="1">AUC<sub>0&#x02013;</sub>
<italic><sub>&#x003c4;</sub></italic> (ng&#x000b7;h/ml)</td><td char="(" rowspan="1" colspan="1">682 (29)</td><td char="(" rowspan="1" colspan="1">678 (23)</td><td char="(" rowspan="1" colspan="1">100 (90&#x02013;111)</td><td char="(" rowspan="1" colspan="1">4038 (20)</td><td char="(" rowspan="1" colspan="1">3951 (26)</td><td char="(" rowspan="1" colspan="1">98 (89&#x02013;109)</td><td char="(" rowspan="1" colspan="1">4134 (23)</td></tr><tr><td rowspan="1" colspan="1">
<italic>t</italic>
<sub>max</sub> (h)</td><td char="(" rowspan="1" colspan="1">3.0 (2.0&#x02013;6.0)</td><td char="(" rowspan="1" colspan="1">3.0 (2.0&#x02013;6.0)</td><td rowspan="1" colspan="1">NA</td><td char="(" rowspan="1" colspan="1">3.0 (2.0&#x02013;4.0)</td><td char="(" rowspan="1" colspan="1">4.0 (2.0&#x02013;6.0)</td><td rowspan="1" colspan="1">NA</td><td char="(" rowspan="1" colspan="1">3.1 (2.0&#x02013;4.2)</td></tr></tbody></table><table-wrap-foot><fn id="TN1"><p>Data are geometric mean (coefficient of variation) for <italic>C</italic>
<sub>max</sub>, and AUC<sub>0&#x02013;</sub>
<italic><sub>&#x003c4;</sub></italic>, and median (range) for <italic>t</italic>
<sub>max</sub>. AUC<sub>0&#x02013;</sub>
<italic><sub>&#x003c4;</sub></italic>&#x02009;=&#x02009;area under the plasma concentration-time curve for the dosing interval; bid&#x02009;=&#x02009;twice daily; <italic>C</italic>
<sub>max</sub>&#x02009;=&#x02009;maximum plasma concentration; LS mean ratio&#x02009;=&#x02009;least squares mean for ticagrelor as a percentage of the least squares mean for ticagrelor/aspirin; NA&#x02009;=&#x02009;not applicable; qd&#x02009;=&#x02009;once daily; <italic>t</italic>
<sub>max</sub>&#x02009;=&#x02009;time to reach peak or maximum concentration.</p></fn><fn id="T1-F1"><label>a</label><p>50 mg bid for 5 days.</p></fn><fn id="T1-F2"><label>b</label><p>200 mg bid for 4 days, then a single 200&#x02009;mg dose for one day.</p></fn><fn id="T1-F3"><label>c</label><p>200 mg bid for 5 days, then a single 200&#x02009;mg dose for one day.</p></fn></table-wrap-foot></table-wrap><p>The plasma concentration-time profiles of ticagrelor (<xref ref-type="fig" rid="F2">Figure 2a</xref>) and AR-C124910XX (<xref ref-type="fig" rid="F2">Figure 2b</xref>), and key pharmacokinetic parameters (<xref ref-type="table" rid="T1">Table I</xref>) were comparable following the administration of ticagrelor with or without 300&#x02009;mg aspirin (Study A). The LS mean ratios were close to 100% for <italic>C</italic>
<sub>max</sub> and AUC<sub>0&#x02013;</sub>
<italic><sub>&#x003c4;</sub></italic> for both ticagrelor and AR-C124910XX (<xref ref-type="table" rid="T1">Table I</xref>).</p><p>Mean <italic>C</italic>
<sub>max</sub>, mean AUC<sub>0&#x02013;</sub>
<italic><sub>&#x003c4;</sub></italic>, and median <italic>t</italic>
<sub>max</sub> for ticagrelor and AR-C124910XX following the co-administration of ticagrelor (200&#x02009;mg bid) with aspirin (75&#x02009;mg qd) (Study B) were comparable with data following ticagrelor (200&#x02009;mg bid) administration with 300&#x02009;mg qd aspirin (Study A; <xref ref-type="table" rid="T1">Table I</xref>).</p></sec><sec id="ss22"><title>Adenosine diphosphate (ADP)-(20&#x02009;&#x000b5;M)-induced platelet aggregation</title><sec id="ss23"><title>Study A: Effect of aspirin on ticagrelor-induced IPA</title><p>Mean final-extent IPA ranged from 62% to 89%, 0&#x02013;12 hours after the last dose of 50&#x02009;mg bid ticagrelor alone (<xref ref-type="fig" rid="F3">Figure 3a</xref>). Almost complete inhibition of ADP-induced platelet aggregation was achieved with 200&#x02009;mg bid ticagrelor (<xref ref-type="fig" rid="F3">Figure 3b</xref>); mean IPA ranged from 95% to 98%, 0&#x02013;12 hours post-dosing. For 24 and 36 hours post-dosing, the mean IPA declined to 88% and 79%, respectively.<fig fig-type="fig" id="F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Inhibition of platelet aggregation (final-extent, 20&#x02009;&#x000b5;M ADP-induced) following administration of ticagrelor (a) 50&#x02009;mg bid for 5 days, and (b) 200&#x02009;mg bid for 4 days then qd for 1&#x02009;day,&#x02009;&#x000b1;&#x02009;once-daily aspirin (300&#x02009;mg) (Study A). Values are mean&#x02009;&#x000b1;&#x02009;SD, <italic>n</italic>&#x02009;=&#x02009;11 or 12 at each time point.</p></caption><graphic xlink:href="PLA-24-615-g003"/></fig>
</p><p>Co-administration of once-daily aspirin (300&#x02009;mg) had no effect on final-extent IPA with either 50&#x02009;mg bid (<xref ref-type="fig" rid="F3">Figure 3a</xref>) or 200 mg bid (<xref ref-type="fig" rid="F3">Figure 3b</xref>) ticagrelor. Mean IPA ranged from 71% to 89% and 94% to 98%, respectively, at 0&#x02013;12&#x02009;hours post-dosing.</p></sec><sec id="ss24"><title>Study B: Effect of aspirin on ticagrelor-induced IPA</title><p>For ticagrelor (200&#x02009;mg bid) co-administered with 75&#x02009;mg aspirin daily, the mean final-extent IPA (ADP-induced) ranged from 91% to 99% at 0&#x02013;12 hours post-dosing (<xref ref-type="fig" rid="F4">Figure 4</xref>).<fig fig-type="fig" id="F4" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Inhibition of platelet aggregation (final-extent, 20&#x02009;&#x000b5;M ADP-induced) following administration of ticagrelor (200&#x02009;mg bid for 5 days then a single 200&#x02009;mg dose for 1&#x02009;day)&#x02009;+&#x02009;aspirin (75&#x02009;mg qd) and clopidogrel (loading dose 300&#x02009;mg on Day 1 then 75&#x02009;mg qd for 5 days)&#x02009;+&#x02009;aspirin (75&#x02009;mg qd) (Study B). Values are mean&#x02009;&#x000b1;&#x02009;SD, <italic>n</italic>&#x02009;=&#x02009;16 at each time point.</p></caption><graphic xlink:href="PLA-24-615-g004"/></fig>
</p></sec><sec id="ss25"><title>Study B: Ticagrelor/aspirin vs. clopidogrel/aspirin</title><p>Ticagrelor/aspirin significantly increased mean final-extent IPA (ADP-induced; 95.8% [coefficient of variation (CV) 6.4%]) compared with aspirin alone (9.3% [CV, 112%]; difference, 86.5% [95% CI, &#x0003c;0.0001&#x02013;90.3%]; <italic>p</italic>&#x02009;&#x0003c;0.0001).</p><p>At steady-state, mean final-extent IPA was higher with ticagrelor/aspirin compared with clopidogrel/aspirin at all time points evaluated (<xref ref-type="fig" rid="F4">Figure 4</xref>). IPA response over the dosing interval remained high with ticagrelor/aspirin as pre-dose final IPA values were &#x0003e;80% in all ticagrelor-treated volunteers and in only 50% of clopidogrel-treated volunteers. Inter-individual variability of IPA parameters was lower with ticagrelor/aspirin vs. clopidogrel/aspirin (<xref ref-type="fig" rid="F4">Figure 4</xref>, <xref ref-type="table" rid="T2">Table II</xref>).<table-wrap id="T2" orientation="portrait" position="float"><label>Table II.&#x02003;</label><caption><p>IPA parameters at final-extent 20&#x02009;&#x000b5;M ADP-induced and collagen-induced aggregation (Study B).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Ticagrelor 200&#x02009;mg bid<xref ref-type="fn" rid="T2-F1"><sup>a</sup></xref>/aspirin 75&#x02009;mg qd (<italic>n</italic>&#x02009;=&#x02009;16)</th><th align="center" rowspan="1" colspan="1">Clopidogrel 300&#x02009;mg load, 75&#x02009;mg qd<xref ref-type="fn" rid="T2-F2"><sup>b</sup></xref>/aspirin 75&#x02009;mg qd (<italic>n</italic>&#x02009;=&#x02009;16)</th><th align="center" rowspan="1" colspan="1">Difference (ticagrelor &#x02013; clopidogrel) (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>-value</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">
<bold>ADP-induced</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">IPA<sub>max</sub> (%)</td><td char="(" rowspan="1" colspan="1">99.5 (2)</td><td char="(" rowspan="1" colspan="1">88.3 (18)</td><td char="(" rowspan="1" colspan="1">11.1 (3.4&#x02013;18.8)</td><td char="(" rowspan="1" colspan="1">0.0077</td></tr><tr><td rowspan="1" colspan="1">TIPA<sub>max</sub> (h)</td><td char="(" rowspan="1" colspan="1">0.0 (0.0&#x02013;4.0)</td><td char="(" rowspan="1" colspan="1">4.0 (0.0&#x02013;12.0)</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">AUEC<sub>0&#x02013;12</sub> (%&#x000b7;h)</td><td char="(" rowspan="1" colspan="1">1163 (10)</td><td char="(" rowspan="1" colspan="1">1002 (25)</td><td char="(" rowspan="1" colspan="1">161 (40&#x02013;283)</td><td char="(" rowspan="1" colspan="1">0.0129</td></tr><tr><td rowspan="1" colspan="1">AUEC<sub>0&#x02013;24</sub> (%&#x000b7;h)</td><td char="(" rowspan="1" colspan="1">2234 (18)</td><td char="(" rowspan="1" colspan="1">1888 (32)</td><td char="(" rowspan="1" colspan="1">346 (38&#x02013;653)</td><td char="(" rowspan="1" colspan="1">0.0302</td></tr><tr><td rowspan="1" colspan="1">
<bold>Collagen-induced</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">IPA<sub>max</sub> (%)</td><td char="(" rowspan="1" colspan="1">83.0 (16)</td><td char="(" rowspan="1" colspan="1">74.1 (18.4)</td><td char="(" rowspan="1" colspan="1">8.7 (3.9&#x02013;13.6)</td><td char="(" rowspan="1" colspan="1">0.0017</td></tr><tr><td rowspan="1" colspan="1">TIPA<sub>max</sub> (h)</td><td char="(" rowspan="1" colspan="1">4.0 (2&#x02013;24)</td><td char="(" rowspan="1" colspan="1">4.0 (2&#x02013;12)</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">AUEC<sub>0&#x02013;12</sub> (%&#x000b7;h)</td><td char="(" rowspan="1" colspan="1">939 (18)</td><td char="(" rowspan="1" colspan="1">836 (19)</td><td char="(" rowspan="1" colspan="1">103 (45&#x02013;161)</td><td char="(" rowspan="1" colspan="1">0.0019</td></tr><tr><td rowspan="1" colspan="1">AUEC<sub>0&#x02013;24</sub> (%&#x000b7;h)</td><td char="(" rowspan="1" colspan="1">1785 (18)</td><td char="(" rowspan="1" colspan="1">1566 (20)</td><td char="(" rowspan="1" colspan="1">219 (92&#x02013;346)</td><td char="(" rowspan="1" colspan="1">0.0023</td></tr></tbody></table><table-wrap-foot><fn id="TN2"><p>Data are mean (coefficient of variation %) for IPA<sub>max</sub> and AUEC; median (range) for TIPA<sub>max</sub>. ADP&#x02009;=&#x02009;adenosine diphosphate; AUEC<sub>0&#x02013;12</sub>, AUEC<sub>0&#x02013;24</sub> area under the effect curve of IPA from 0&#x02013;12 hours and 0&#x02013;24 hours, respectively; CI&#x02009;=&#x02009;confidence interval; IPA&#x02009;=&#x02009;inhibition of platelet aggregation; IPA<sub>max</sub>&#x02009;=&#x02009;maximum IPA; TIPA<sub>max</sub>&#x02009;=&#x02009;time to IPA<sub>max</sub>. <italic>p</italic>-values are for ticagrelor/aspirin comparison to clopidogrel/aspirin dosing using ANOVA.</p></fn><fn id="T2-F1"><label>a</label><p>200 mg bid for 5 days then a single 200&#x02009;mg dose for one day.</p></fn><fn id="T2-F2"><label>b</label><p>300 mg for one day then 75&#x02009;mg qd for 5 days.</p></fn></table-wrap-foot></table-wrap>
</p><p>Mean IPA<sub>max</sub> was significantly higher with ticagrelor/aspirin vs. clopidogrel/aspirin (<italic>p</italic>&#x02009;=&#x02009;0.0077; <xref ref-type="table" rid="T2">Table II</xref>). With ticagrelor/aspirin, 100% IPA<sub>max</sub> was achieved in 14/16 volunteers and was &#x0003e;94% in 2/16 volunteers. In contrast, with clopidogrel/aspirin the final IPA<sub>max</sub> was &#x0003e;80% in 7/16 volunteers, 30&#x02013;80% in 6/16 volunteers and &#x0003c;30% in 3/16 volunteers. AUEC<sub>0&#x02013;12</sub> and AUEC<sub>0&#x02013;24</sub> were also significantly higher with ticagrelor/aspirin vs. clopidogrel/aspirin (<xref ref-type="table" rid="T2">Table II</xref>).</p></sec></sec><sec id="ss26"><title>Collagen-induced platelet aggregation</title><sec id="ss27"><title>Study A: Effect of aspirin and ticagrelor</title><p>At 2 hours post-dosing with 300&#x02009;mg aspirin alone, the mean (standard error of the mean [SEM]) final-extent IPA was 37% (&#x000b1; 4.2%). With ticagrelor alone, the mean final-extent IPA ranged from 7&#x02013;9% (4&#x02013;12 hours post-dose) and 12&#x02013;20% (2&#x02013;12 hours post-dose) with 50&#x02009;mg bid and 200&#x02009;mg bid ticagrelor, respectively (<xref ref-type="fig" rid="F5">Figure 5a</xref>).<fig fig-type="fig" id="F5" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Inhibition of platelet aggregation (final-extent, collagen-induced) following the administration of (a) ticagrelor at 50&#x02009;mg bid for 5 days, and 200&#x02009;mg bid for 4 days then qd for 1&#x02009;day,&#x02009;&#x000b1;&#x02009;once-daily aspirin (300&#x02009;mg) (Study A), and (b) ticagrelor (200&#x02009;mg bid for 5 days then a single 200&#x02009;mg dose for 1&#x02009;day)&#x02009;+&#x02009;aspirin (75&#x02009;mg qd) and clopidogrel (loading dose 300&#x02009;mg on Day 1 then 75&#x02009;mg qd for 5 days)&#x02009;+&#x02009;aspirin (75&#x02009;mg qd) (Study B). Values are mean&#x02009;&#x000b1;&#x02009;SD.</p></caption><graphic xlink:href="PLA-24-615-g005"/></fig>
</p><p>The range of mean IPA was 66&#x02013;74% (4&#x02013;12 hours post-dose) and 72&#x02013;76% (2&#x02013;12 hours post-dose) with 50&#x02009;mg bid and 200&#x02009;mg bid ticagrelor co-administered with aspirin (300&#x02009;mg) once-daily, respectively (<xref ref-type="fig" rid="F5">Figure 5a</xref>).</p></sec><sec id="ss28"><title>Study B: Effect of aspirin and ticagrelor</title><p>At 2 hours post-dosing with 75&#x02009;mg aspirin alone, the mean (SEM) final-extent IPA was 38% (&#x000b1; 3.6%). For ticagrelor (200&#x02009;mg bid) co-administered with 75&#x02009;mg aspirin daily, the mean final-extent IPA (collagen-induced) ranged from 74% to 82% at 2&#x02013;12 hours post-dosing (<xref ref-type="fig" rid="F5">Figure 5b</xref>).</p></sec><sec id="ss29"><title>Study B: Ticagrelor/aspirin vs. clopidogrel/aspirin</title><p>For collagen-induced platelet aggregation, mean final-extent IPA was higher with ticagrelor/aspirin vs. clopidogrel/aspirin at all time points evaluated (<xref ref-type="fig" rid="F5">Figure 5b</xref>). IPA<sub>max</sub>, AUEC<sub>0&#x02013;12</sub>, and AUEC<sub>0&#x02013;24</sub> were also significantly higher with ticagrelor/aspirin vs. clopidogrel/aspirin (<xref ref-type="table" rid="T2">Table II</xref>).</p></sec></sec><sec id="ss30"><title>Bleeding times</title><sec id="ss31"><title>Study A: Effect of ticagrelor with and without aspirin (Simplate method)</title><p>At steady state, both doses of ticagrelor (no aspirin) increased bleeding time compared with baseline (<xref ref-type="table" rid="T3">Table III</xref>). Co-administration of aspirin (300&#x02009;mg qd) with either dose of ticagrelor had no effect on bleeding times compared to ticagrelor alone (<xref ref-type="table" rid="T3">Table III</xref>). Following the administration of 200&#x02009;mg bid ticagrelor with or without aspirin, most volunteers had bleeding times &#x0003e;30 minutes (1800 seconds).<table-wrap id="T3" orientation="portrait" position="float"><label>Table III.&#x02003;</label><caption><p>Mean bleeding times following multiple dosing of ticagrelor&#x02009;&#x000b1;&#x02009;once-daily aspirin and clopidogrel with once-daily aspirin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Method/treatment</th><th align="center" rowspan="1" colspan="1">Bleeding time, mean&#x02009;&#x000b1;&#x02009;SD (range)<xref ref-type="fn" rid="T3-F1"><sup>&#x02020;</sup></xref>
</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Study A (<italic>n</italic>&#x02009;=&#x02009;13&#x02013;16)<xref ref-type="fn" rid="T3-F1"><sup>a</sup></xref>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold><italic>Simplate method</italic></bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Baseline (at enrolment)</td><td char="(" rowspan="1" colspan="1">274&#x02009;&#x000b1;&#x02009;64 (120&#x02013;390)</td></tr><tr><td rowspan="1" colspan="1">Ticagrelor (50&#x02009;mg bid<xref ref-type="fn" rid="T3-F2"><sup>b</sup></xref>)</td><td char="(" rowspan="1" colspan="1">1376&#x02009;&#x000b1;&#x02009;527 (540&#x02013;1800)</td></tr><tr><td rowspan="1" colspan="1">Ticagrelor/aspirin (50&#x02009;mg bid<xref ref-type="fn" rid="T3-F2"><sup>b</sup></xref>/300&#x02009;mg qd)</td><td char="(" rowspan="1" colspan="1">1622&#x02009;&#x000b1;&#x02009;377 (720&#x02013;1800)</td></tr><tr><td rowspan="1" colspan="1">Ticagrelor (200&#x02009;mg bid<xref ref-type="fn" rid="T3-F2"><sup>&#x000a7;</sup></xref>)</td><td char="(" rowspan="1" colspan="1">1800&#x02009;&#x000b1;&#x02009;0 (1800&#x02013;1800)</td></tr><tr><td rowspan="1" colspan="1">Ticagrelor/aspirin (200&#x02009;mg bid<xref ref-type="fn" rid="T3-F2"><sup>&#x000a7;</sup></xref>/300&#x02009;mg qd)</td><td char="(" rowspan="1" colspan="1">1800&#x02009;&#x000b1;&#x02009;0 (1800&#x02013;1800)</td></tr><tr><td rowspan="1" colspan="1">
<bold><italic>Lancet method</italic></bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Baseline (at enrolment)</td><td char="(" rowspan="1" colspan="1">159&#x02009;&#x000b1;&#x02009;54 (53&#x02013;240)</td></tr><tr><td rowspan="1" colspan="1">Ticagrelor (200&#x02009;mg bid<xref ref-type="fn" rid="T3-F2"><sup>&#x000a7;</sup></xref>)</td><td char="(" rowspan="1" colspan="1">250&#x02009;&#x000b1;&#x02009;77 (135&#x02013;435)</td></tr><tr><td rowspan="1" colspan="1">Ticagrelor/aspirin (200&#x02009;mg bid<xref ref-type="fn" rid="T3-F2"><sup>&#x000a7;</sup></xref>/300&#x02009;mg qd)</td><td char="(" rowspan="1" colspan="1">541&#x02009;&#x000b1;&#x02009;469 (195&#x02013;1800)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Study B (<italic>n</italic>&#x02009;=&#x02009;8&#x02013;16)</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold><italic>Lancet method</italic></bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Baseline (at screening)</td><td char="(" rowspan="1" colspan="1">2.2&#x02009;&#x000b1;&#x02009;0.7 (1.1&#x02013;3.0)</td></tr><tr><td rowspan="1" colspan="1">Aspirin (300/75&#x02009;mg qd<xref ref-type="fn" rid="T3-F3"><sup>c</sup></xref>)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;4&#x02009;h post-dose on Day 3</td><td char="(" rowspan="1" colspan="1">2.7&#x02009;&#x000b1;&#x02009;0.6 (2.0&#x02013;3.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Pre-dose on Day 4</td><td char="(" rowspan="1" colspan="1">2.2&#x02009;&#x000b1;&#x02009;0.4 (1.5&#x02013;2.8)</td></tr><tr><td rowspan="1" colspan="1">Ticagrelor/aspirin (200&#x02009;mg bid<xref ref-type="fn" rid="T3-F4"><sup>d</sup></xref>/75&#x02009;mg qd)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Pre-dose</td><td char="(" rowspan="1" colspan="1">13.1&#x02009;&#x000b1;&#x02009;10.0 (2.5&#x02013;30.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;4&#x02009;h post-dose</td><td char="(" rowspan="1" colspan="1">8.7&#x02009;&#x000b1;&#x02009;8.4 (2.3&#x02013;30.0)</td></tr><tr><td rowspan="1" colspan="1">Clopidogrel<xref ref-type="fn" rid="T3-F5"><sup>e</sup></xref>/aspirin (75&#x02009;mg qd/75&#x02009;mg qd)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Pre-dose</td><td char="(" rowspan="1" colspan="1">4.4&#x02009;&#x000b1;&#x02009;1.5 (2.0&#x02013;8.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;4&#x02009;h post-dose</td><td char="(" rowspan="1" colspan="1">4.8&#x02009;&#x000b1;&#x02009;1.9 (2.0&#x02013;8.5)</td></tr></tbody></table><table-wrap-foot><fn id="TN3"><p>bid&#x02009;=&#x02009;twice daily; h&#x02009;=&#x02009;hours; qd&#x02009;=&#x02009;once daily; SD&#x02009;=&#x02009;standard deviation.</p></fn><fn id="T3-F1"><label>a</label><p>Time point&#x02009;=&#x02009;4 hours post-dosing, except for baseline values;<sup>&#x02020;</sup>bleeding times are in seconds for Study A, and minutes for Study B.</p></fn><fn id="T3-F2"><label>b</label><p>50 mg bid for 5 days; <sup>&#x000a7;</sup>200&#x02009;mg bid for 4 days then a single 200&#x02009;mg dose for one day.</p></fn><fn id="T3-F3"><label>c</label><p>Loading dose 300&#x02009;mg on day 1 then 75&#x02009;mg qd thereafter.</p></fn><fn id="T3-F4"><label>d</label><p>200 mg bid for 5 days then a single 200&#x02009;mg dose for one day.</p></fn><fn id="T3-F5"><label>e</label><p>300 mg for one day then 75&#x02009;mg qd for 5 days.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="ss32"><title>Study A: Effect of ticagrelor with and without aspirin (lancet method)</title><p>At the end of ticagrelor administration (50&#x02009;mg bid for 5 days, followed by 200&#x02009;mg bid for 4 days then 200&#x02009;mg once) mean bleeding time at 4 hours post-dose was increased vs. baseline. Co-administration of aspirin (300&#x02009;mg qd) further prolonged the bleeding time (<xref ref-type="table" rid="T3">Table III</xref>). Individual bleeding times &#x0003e;30 minutes were observed at four time points; all of these occurred with ticagrelor/aspirin treatment.</p></sec><sec id="ss33"><title>Study B: Effect of ticagrelor with and without aspirin (lancet method)</title><p>Aspirin alone (75&#x02009;mg qd) did not increase bleeding time vs. baseline (<xref ref-type="table" rid="T3">Table III</xref>). Multiple (200 mg bid, 5 days) doses of ticagrelor co-administered with aspirin (75&#x02009;mg qd) increased the bleeding time (<xref ref-type="table" rid="T3">Table III</xref>). However, bleeding time with ticagrelor/aspirin dosing did not appear to correlate with ticagrelor plasma concentrations; on Day 9 mean (standard deviation [SD]) bleeding time pre-dose was 13.1 (10.0) minutes and decreased at 4 hours post-dose to 8.7 (8.4) minutes. At the latter time point, plasma ticagrelor concentrations were two-fold higher than pre-dose values.</p></sec><sec id="ss34"><title>Study B: Comparative effects of ticagrelor/aspirin vs. clopidogrel/aspirin (lancet method)</title><p>Clopidogrel/aspirin (75&#x02009;mg qd/75&#x02009;mg qd for 5 days) administration prolonged the mean lancet bleeding time (<xref ref-type="table" rid="T3">Table III</xref>). At all time points evaluated, bleeding times were longer with ticagrelor/aspirin (200&#x02009;mg bid/75&#x02009;mg qd for 5 days) vs. clopidogrel/aspirin (<xref ref-type="table" rid="T3">Table III</xref>).</p></sec></sec><sec id="ss35"><title>Tolerability</title><p>Overall, ticagrelor alone, ticagrelor with aspirin (75&#x02009;mg qd and 300&#x02009;mg qd), and clopidogrel/aspirin (75&#x02009;mg qd/75&#x02009;mg qd) were well tolerated. There were no serious AEs or deaths in either study.</p><p>In Study A, three volunteers discontinued treatment due to bleeding-related AEs; possibly ticagrelor-related. One volunteer had moderate epistaxis on Days 2 and 3 of ticagrelor (50&#x02009;mg bid)/aspirin co-administration. Another volunteer discontinued due to hematoma (moderate), petechiae (mild), and urticaria (mild) commencing on Day 9 (ticagrelor 200&#x02009;mg bid/aspirin). Moderate gingivitis, between Days 5 and 7 of ticagrelor 200&#x02009;mg bid dosing, resulted in the discontinuation of another volunteer. Overall, nine volunteers had 14 AEs: four volunteers had four AEs with ticagrelor alone; six volunteers had 10 AEs with ticagrelor/aspirin; one volunteer had an AE in both periods. The most common AEs (&#x0003e;10% volunteers) were headache (<italic>n</italic>&#x02009;=&#x02009;2 with ticagrelor) and petechiae (<italic>n</italic>&#x02009;=&#x02009;2 with ticagrelor/aspirin).</p><p>In Study B, four volunteers had five AEs (mild). During ticagrelor/aspirin administration, three volunteers had one AE each (diarrhea; epistaxis; dental discomfort [not treatment related]). One volunteer had two AEs (nausea and flatulence) during treatment with clopidogrel/aspirin</p><p>In both studies, there were no clinically meaningful changes in hematology, clinical chemistry, urinalysis, vital signs, physical findings, or ECG data with ticagrelor, ticagrelor/aspirin, or clopidogrel/aspirin.</p></sec></sec><sec sec-type="discussion" id="ss36"><title>Discussion</title><p>The previously unpublished data presented here from two early studies in the ticagrelor development programme (2002&#x02013;2003) indicate that aspirin is not associated with a pharmacokinetic or pharmacodynamic (IPA) effect on ticagrelor. Our current findings on IPA (ADP-induced) by ticagrelor are similar to those shown in a previous report <xref ref-type="bibr" rid="b21">[21]</xref>. Also in line with previous data <xref ref-type="bibr" rid="b23">[23]</xref>, aspirin alone had minimal inhibitory effect on ADP-induced platelet aggregation (approximately 10%; Study B). In addition, the degree of IPA (ADP-induced) by ticagrelor was unaffected by aspirin (300&#x02009;mg qd, Study A), and near-maximal IPA was achieved with ticagrelor (200&#x02009;mg bid)/75&#x02009;mg qd aspirin (Study B). These findings showing minimal effects of aspirin on ticagrelor IPA (ADP-induced) are unsurprising since the mechanism of action for IPA differs between these compounds. Aspirin blocks the cyclooxygenase activity thereby inhibiting arachidonic acid-induced platelet aggregation <xref ref-type="bibr" rid="b12">[12]</xref>, whereas ticagrelor is a P2Y<sub>12</sub> receptor antagonist and inhibits ADP-induced platelet aggregation <xref ref-type="bibr" rid="b1">[1]</xref>.</p><p>Collagen was also used as an agonist of platelet aggregation in the present studies. Aspirin alone inhibited collagen-induced platelet aggregation by a magnitude similar to that observed previously in healthy volunteers (e.g. 37% IPA in males with 81 and 325&#x02009;mg aspirin qd for 14 days) <xref ref-type="bibr" rid="b24">[24]</xref>. Ticagrelor alone at steady state slightly inhibited collagen-induced platelet aggregation in Study A. However, ticagrelor had a synergistic effect with the IPA associated with aspirin alone, since the IPA observed after ticagrelor (50 or 200&#x02009;mg bid)/aspirin (300&#x02009;mg qd) was higher than either drug administered alone. Moreover, IPA was similar after ticagrelor 200&#x02009;mg bid/aspirin 300&#x02009;mg qd (Study A) and ticagrelor 200&#x02009;mg bid/aspirin 75&#x02009;mg qd (Study B).</p><p>Pharmacokinetic data from the two present studies also demonstrate a lack of interaction between ticagrelor and aspirin. The steady-state pharmacokinetic parameters of ticagrelor and AR-C124910XX following the administration of ticagrelor alone (Study A) were consistent with previously reported data <xref ref-type="bibr" rid="b21">[21]</xref>. Co-administration of aspirin (300&#x02009;mg qd; Study A) with both ticagrelor doses did not affect the pharmacokinetic parameters of either the parent compound or its major metabolite. In addition, the pharmacokinetic data with 200&#x02009;mg bid ticagrelor/300&#x02009;mg qd aspirin (Study A) were similar to those with 200&#x02009;mg bid ticagrelor/75&#x02009;mg qd aspirin (Study B). Our findings with ticagrelor plus aspirin in healthy volunteers are broadly consistent with steady-state pharmacokinetic parameters of ticagrelor and AR-C124910XX in the Phase II Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non-ST segment Elevation myocardial infarction (DISPERSE) trials, in which ticagrelor was co-administered with aspirin (75&#x02009;mg qd) to patients with atherosclerosis <xref ref-type="bibr" rid="b11">[11]</xref> or ACS <xref ref-type="bibr" rid="b10">[10]</xref>, <xref ref-type="bibr" rid="b25">[25]</xref>. Collectively, these findings demonstrate that aspirin co-administration at 75 or 300&#x02009;mg qd did not affect exposure to ticagrelor or AR-C124910XX.</p><p>The therapeutic regimen of clopidogrel/aspirin was included in one of our studies (Study B) for comparative purposes. In this study, ADP-induced IPA with ticagrelor (200&#x02009;mg bid)/aspirin (75&#x02009;mg qd) was more rapid, reached higher levels, and was less variable compared with clopidogrel/aspirin. A greater level of collagen-induced IPA was also achieved with ticagrelor/aspirin than clopidogrel/aspirin. The current observations of higher ticagrelor IPA activity vs. clopidogrel confirm previously reported results in healthy volunteers (no aspirin <xref ref-type="bibr" rid="b21">[21]</xref>), and in patients (with aspirin <xref ref-type="bibr" rid="b10">[10]</xref>, <xref ref-type="bibr" rid="b11">[11]</xref>).</p><p>Bleeding times in both studies highlighted several issues, including methodology factors. In Study A, data suggest that the lancet method was more sensitive than the Simplate method for detecting an increase in bleeding time. The two methods indicated an increase in bleeding time vs. baseline for ticagrelor of different magnitudes, and, in contrast to the lancet method, the Simplate method did not detect an increase in bleeding time on co-administration with aspirin (300&#x02009;mg qd). However, in Study B, lancet bleeding times did not correlate with aspirin dose or bleeding-related AEs. Overall, these results demonstrate the unreliability of bleeding tests in predicting bleeding risk.</p><p>Ticagrelor alone or with aspirin was well tolerated at the studied doses, consistent with previously published studies in healthy volunteers <xref ref-type="bibr" rid="b9">[9]</xref>, <xref ref-type="bibr" rid="b21">[21]</xref>, <xref ref-type="bibr" rid="b26">[26]</xref>, or in patients with atherosclerosis <xref ref-type="bibr" rid="b11">[11]</xref>, or ACS <xref ref-type="bibr" rid="b25">[25]</xref>. PLATO data have also shown that the long-term administration of ticagrelor (90&#x02009;mg bid) and aspirin (various dose levels) was well tolerated with no increase in overall rates of major bleeding vs. clopidogrel/aspirin <xref ref-type="bibr" rid="b2">[2]</xref>.</p><p>A prespecified subgroup analysis of the PLATO trial demonstrated a significant interaction between treatment and region (<italic>p</italic>&#x02009;=&#x02009;0.045), with attenuated benefit associated with ticagrelor being observed in North America compared with the rest of the world <xref ref-type="bibr" rid="b2">[2]</xref>. Two subsequent analyses have noted that play of chance cannot be ruled out as the reason for the interaction, and the regional difference may be explained by an underlying statistical interaction with aspirin maintenance dose <xref ref-type="bibr" rid="b19">[19]</xref>.</p><p>A <italic>post-hoc</italic> subgroup analysis of the PLATO trial (Cox regression with median maintenance dose) showed that, in patients taking &#x02264;100&#x02009;mg maintenance aspirin, ticagrelor was associated with superior outcomes compared with clopidogrel (adjusted HR 0.77 [95% CI, 0.69&#x02212;0.86]. In patients taking maintenance aspirin dose &#x02265;300&#x02009;mg, HR of 1.45 (95% CI, 1.01&#x02013;2.09) favored clopidogrel. The interaction between aspirin dose category and treatment is significant (<italic>p</italic>&#x02009;=&#x02009;0.00006) <xref ref-type="bibr" rid="b19">[19]</xref>. Subsequently, the FDA recommended that ticagrelor be co-administered with 75&#x02013;100&#x02009;mg qd aspirin <xref ref-type="bibr" rid="b3">[3]</xref>.</p><p>The mechanism of the antagonism between high-dose aspirin and ticagrelor on clinical outcomes is currently under investigation, a detailed discussion of which is beyond the scope of this manuscript. In brief, it is thought that the antagonism of P2Y<sub>12</sub> receptors, such as that seen with ticagrelor, may also inhibit thromboxane-induced platelet activation <xref ref-type="bibr" rid="b27">[27]</xref>, <xref ref-type="bibr" rid="b28">[28]</xref> in addition to ADP-dependent platelet activation. Consequently, aspirin-induced blockade of thromboxane production, which reaches maximum effect at relatively low doses, will be unable to provide additional IPA <xref ref-type="bibr" rid="b27">[27]</xref>, <xref ref-type="bibr" rid="b28">[28]</xref>.</p><p>The present studies were performed in healthy volunteers who had no evident coronary artery disease. In addition, the doses of ticagrelor and aspirin employed in these two studies differed from those used in the PLATO trial, i.e. ticagrelor 180&#x02009;mg loading dose followed by 90&#x02009;mg bid <xref ref-type="bibr" rid="b2">[2]</xref>. Aspirin maintenance doses of 75&#x02013;100&#x02009;mg daily were recommended in the PLATO study, with 325&#x02009;mg daily aspirin recommended in patients who received a stent, but as previously noted, higher aspirin doses were used in the USA <xref ref-type="bibr" rid="b19">[19]</xref>. However, aside from these study limitations, these data suggest that the effects of aspirin on the pharmacokinetics or pharmacodynamics (IPA) of ticagrelor are unlikely to be responsible for differences observed in the PLATO trial.</p></sec><sec sec-type="conclusion" id="ss37"><title>Conclusions</title><p>Ticagrelor pharmacokinetics following the administration of 50&#x02009;mg bid and 200&#x02009;mg bid ticagrelor doses were unaffected by the co-administration of 300&#x02009;mg qd aspirin. This concomitant dose of aspirin also had no effect on ticagrelor-induced IPA. Ticagrelor/aspirin co-administration was well tolerated at all dose combinations evaluated.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors wish to thank Dr Thierry Duvauchelle and his team for conducting both studies at ASTER, Paris, France. Staff at York Bioanalytical Solutions, York, UK, are acknowledged for their pharmacokinetic analyses. We also thank Jackie Phillipson (Gardiner-Caldwell Communications), who provided medical writing support funded by AstraZeneca.</p><p>
<bold><italic>Declaration of interest:</italic></bold> Drs Butler, Maya, and Teng are employees of AstraZeneca.</p></ack><ref-list><title>References</title><ref id="b1"><label>1. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husted</surname><given-names>S</given-names></name><name><surname>van Giezen</surname><given-names>JJ</given-names></name></person-group><article-title>Ticagrelor: The first reversibly binding oral P2Y receptor antagonist</article-title><source>Cardiovasc Ther</source><year>2009</year><volume>27</volume><fpage>259</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">19604248</pub-id></element-citation></ref><ref id="b2"><label>2. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallentin</surname><given-names>L</given-names></name><name><surname>Becker</surname><given-names>RC</given-names></name><name><surname>Budaj</surname><given-names>A</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Emanuelsson</surname><given-names>H</given-names></name><name><surname>Held</surname><given-names>C</given-names></name><name><surname>Horrow</surname><given-names>J</given-names></name><name><surname>Husted</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>S</given-names></name><name><surname>Katus</surname><given-names>H</given-names></name></person-group><etal>et al</etal><article-title>for the PLATO investigators. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>1045</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">19717846</pub-id></element-citation></ref><ref id="b3"><label>3. </label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Brilinta TM</surname><given-names>US</given-names></name></person-group><comment>full prescribing information, July 2011. [Accessed 18 July 2012] Available at: <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022433s000lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022433s000lbl.pdf</ext-link></comment></element-citation></ref><ref id="b4"><label>4. </label><element-citation publication-type="web"><comment>Brilique, summary of product characteristics, 2010. [Accessed 18 July 2012]. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001241/WC500100494.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001241/WC500100494.pdf</ext-link></comment></element-citation></ref><ref id="b5"><label>5. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Akl</surname><given-names>EA</given-names></name><name><surname>Crowther</surname><given-names>M</given-names></name><name><surname>Gutterman</surname><given-names>DD</given-names></name><name><surname>Schu&#x000fc;nemann</surname><given-names>HJ</given-names></name></person-group><article-title>Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College fo Chest Physicians evidence-based clinical practice guidelines</article-title><source>Chest</source><year>2012</year><volume>141</volume><fpage>7S</fpage><lpage>47S</lpage><pub-id pub-id-type="pmid">22315257</pub-id></element-citation></ref><ref id="b6"><label>6. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamm</surname><given-names>CW</given-names></name><name><surname>Bassand</surname><given-names>JP</given-names></name><name><surname>Agewall</surname><given-names>S</given-names></name><name><surname>Bax</surname><given-names>J</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Bueno</surname><given-names>H</given-names></name><name><surname>Caso</surname><given-names>P</given-names></name><name><surname>Dudek</surname><given-names>D</given-names></name><name><surname>Gielen</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>K</given-names></name></person-group><etal>et al</etal><article-title>ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><fpage>2999</fpage><lpage>3054</lpage><pub-id pub-id-type="pmid">21873419</pub-id></element-citation></ref><ref id="b7"><label>7. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>GN</given-names></name><name><surname>Bates</surname><given-names>ER</given-names></name><name><surname>Blankenship</surname><given-names>JC</given-names></name><name><surname>Bailey</surname><given-names>SR</given-names></name><name><surname>Bittl</surname><given-names>JA</given-names></name><name><surname>Cercek</surname><given-names>B</given-names></name><name><surname>Chambers</surname><given-names>CE</given-names></name><name><surname>Ellis</surname><given-names>SG</given-names></name><name><surname>Guyton</surname><given-names>RA</given-names></name><name><surname>Hollenberg</surname><given-names>SM</given-names></name></person-group><etal>et al</etal><article-title>2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>58</volume><fpage>e44</fpage><lpage>e122</lpage><pub-id pub-id-type="pmid">22070834</pub-id></element-citation></ref><ref id="b8"><label>8. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>R</given-names></name><name><surname>Oliver</surname><given-names>S</given-names></name><name><surname>Hayes</surname><given-names>M</given-names></name><name><surname>Butler</surname><given-names>K</given-names></name></person-group><article-title>Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects</article-title><source>Drug Metab Dispos</source><year>2010</year><volume>38</volume><fpage>1514</fpage><lpage>1521</lpage><pub-id pub-id-type="pmid">20551239</pub-id></element-citation></ref><ref id="b9"><label>9. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>R</given-names></name><name><surname>Butler</surname><given-names>K</given-names></name></person-group><article-title>Pharmacokinetics, pharmacodynamics, tolerability, and safety of single ascending doses of ticagrelor: A reversibly binding oral P2Y<sub>12</sub> receptor antagonist in healthy subjects</article-title><source>Eur J Clin Pharmacol</source><year>2010</year><volume>66</volume><fpage>487</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">20091161</pub-id></element-citation></ref><ref id="b10"><label>10. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storey</surname><given-names>RF</given-names></name><name><surname>Husted</surname><given-names>S</given-names></name><name><surname>Harrington</surname><given-names>RA</given-names></name><name><surname>Heptinstall</surname><given-names>S</given-names></name><name><surname>Wilcox</surname><given-names>RG</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name><name><surname>Wickens</surname><given-names>M</given-names></name><name><surname>Emanuelsson</surname><given-names>H</given-names></name><name><surname>Gurbel</surname><given-names>P</given-names></name><name><surname>Grande</surname><given-names>P</given-names></name></person-group><etal>et al</etal><article-title>Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y<sub>12</sub> receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>50</volume><fpage>1852</fpage><lpage>1856</lpage><pub-id pub-id-type="pmid">17980251</pub-id></element-citation></ref><ref id="b11"><label>11. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husted</surname><given-names>S</given-names></name><name><surname>Emanuelsson</surname><given-names>H</given-names></name><name><surname>Heptinstall</surname><given-names>S</given-names></name><name><surname>Sandset</surname><given-names>PM</given-names></name><name><surname>Wickens</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name></person-group><article-title>Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y<sub>12</sub> antagonise AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><fpage>1038</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">16476694</pub-id></element-citation></ref><ref id="b12"><label>12. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>KK</given-names></name></person-group><article-title>Aspirin and other cyclooxygenase inhibitors: New therapeutic insights</article-title><source>Semin Vasc Med</source><year>2003</year><volume>3</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">15199473</pub-id></element-citation></ref><ref id="b13"><label>13. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patrignani</surname><given-names>P</given-names></name><name><surname>Filabozzi</surname><given-names>P</given-names></name><name><surname>Patrono</surname><given-names>C</given-names></name></person-group><article-title>Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects</article-title><source>J Clin Invest.</source><year>1982</year><volume>69</volume><fpage>1366</fpage><lpage>1372</lpage><pub-id pub-id-type="pmid">7045161</pub-id></element-citation></ref><ref id="b14"><label>14. </label><element-citation publication-type="journal"><person-group><collab>Antithrombotic Trialists&#x02019; Collaboration</collab></person-group><article-title>Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infraction, and stroke in high risk patients</article-title><source>Br Med J</source><year>2002</year><volume>324</volume><fpage>71</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">11786451</pub-id></element-citation></ref><ref id="b15"><label>15. </label><element-citation publication-type="journal"><person-group><collab>Antithrombotic Trialists' Collaboration</collab></person-group><article-title>Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>1849</fpage><lpage>1860</lpage><pub-id pub-id-type="pmid">19482214</pub-id></element-citation></ref><ref id="b16"><label>16. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patrono</surname><given-names>C</given-names></name><name><surname>Coller</surname><given-names>B</given-names></name><name><surname>Dalen</surname><given-names>JE</given-names></name><name><surname>FitzGerald</surname><given-names>GA</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Gent</surname><given-names>M</given-names></name><name><surname>Hirsh</surname><given-names>J</given-names></name><name><surname>Roth</surname><given-names>G</given-names></name></person-group><article-title>Platelet-active drugs: The relationships among dose, effectiveness and side effects</article-title><source>Chest</source><year>2001</year><volume>119</volume><fpage>39S</fpage><lpage>63S</lpage><pub-id pub-id-type="pmid">11157642</pub-id></element-citation></ref><ref id="b17"><label>17. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>CL</given-names></name><name><surname>Smyth</surname><given-names>S</given-names></name><name><surname>Montalescot</surname><given-names>G</given-names></name><name><surname>Steinhubl</surname><given-names>SR</given-names></name></person-group><article-title>Aspirin dose for the prevention of cardiovascular disease: A systematic review</article-title><source>JAMA</source><year>2007</year><volume>297</volume><fpage>2018</fpage><lpage>2024</lpage><pub-id pub-id-type="pmid">17488967</pub-id></element-citation></ref><ref id="b18"><label>18. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>JS</given-names></name><name><surname>Sallum</surname><given-names>RH</given-names></name><name><surname>Katona</surname><given-names>B</given-names></name><name><surname>Maya</surname><given-names>J</given-names></name><name><surname>Ranganathan</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Mwamburi</surname><given-names>M</given-names></name></person-group><article-title>Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature</article-title><source>Am Heart J</source><year>2012</year><volume>164</volume><fpage>153</fpage><lpage>162.e5</lpage><pub-id pub-id-type="pmid">22877800</pub-id></element-citation></ref><ref id="b19"><label>19. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahaffey</surname><given-names>KW</given-names></name><name><surname>Wojdyla</surname><given-names>DM</given-names></name><name><surname>Carroll</surname><given-names>K</given-names></name><name><surname>Becker</surname><given-names>RC</given-names></name><name><surname>Storey</surname><given-names>RF</given-names></name><name><surname>Angiolillo</surname><given-names>DJ</given-names></name><name><surname>Held</surname><given-names>C</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>James</surname><given-names>S</given-names></name><name><surname>Pieper</surname><given-names>KS</given-names></name></person-group><etal>et al</etal><article-title>on behalf of the PLATO investigators. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial</article-title><source>Circulation</source><year>2011</year><volume>124</volume><fpage>544</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">21709065</pub-id></element-citation></ref><ref id="b20"><label>20. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sill&#x000e9;n</surname><given-names>H</given-names></name><name><surname>Cook</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>P</given-names></name></person-group><article-title>Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry</article-title><source>J Chromatogr B.</source><year>2010</year><volume>878</volume><fpage>2299</fpage><lpage>2306</lpage></element-citation></ref><ref id="b21"><label>21. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>K</given-names></name><name><surname>Teng</surname><given-names>R</given-names></name></person-group><article-title>Pharmacokinetics, pharmacodynamics and safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers</article-title><source>Br J Clin Pharmacol</source><year>2010</year><volume>70</volume><fpage>65</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">20642549</pub-id></element-citation></ref><ref id="b22"><label>22. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00160;r&#x000e1;mek</surname><given-names>R</given-names></name><name><surname>&#x00160;r&#x000e1;mek</surname><given-names>A</given-names></name><name><surname>Koster</surname><given-names>T</given-names></name><name><surname>Briet</surname><given-names>E</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name></person-group><article-title>A randomized and blinded comparison of three bleeding time techniques: The Ivy method, and the Simplate II&#x000ae; method in two directions</article-title><source>Thromb Haemost</source><year>1992</year><volume>67</volume><fpage>514</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">1519210</pub-id></element-citation></ref><ref id="b23"><label>23. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penz</surname><given-names>SM</given-names></name><name><surname>Bernlochner</surname><given-names>I</given-names></name><name><surname>T&#x000f3;th</surname><given-names>O</given-names></name><name><surname>Lorenz</surname><given-names>R</given-names></name><name><surname>Calatzis</surname><given-names>A</given-names></name><name><surname>Siess</surname><given-names>W</given-names></name></person-group><article-title>Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y<sub>12</sub> antagonists by using multiple electrode aggregometry</article-title><source>Thromb J</source><year>2010</year><volume>8</volume><fpage>9</fpage><pub-id pub-id-type="pmid">20465804</pub-id></element-citation></ref><ref id="b24"><label>24. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qayyum</surname><given-names>R</given-names></name><name><surname>Becker</surname><given-names>DM</given-names></name><name><surname>Yanek</surname><given-names>LR</given-names></name><name><surname>Moy</surname><given-names>TF</given-names></name><name><surname>Becker</surname><given-names>LC</given-names></name><name><surname>Faraday</surname><given-names>N</given-names></name><name><surname>Vaidya</surname><given-names>D</given-names></name></person-group><article-title>Platelet inhibition by 81 and 325 mg aspirin daily in men vs. women without clinically apparent cardiovascular disease</article-title><source>Am J Cardiol</source><year>2008</year><volume>101</volume><fpage>1359</fpage><lpage>1363</lpage><pub-id pub-id-type="pmid">18435972</pub-id></element-citation></ref><ref id="b25"><label>25. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Husted</surname><given-names>S</given-names></name><name><surname>Harrington</surname><given-names>RA</given-names></name><name><surname>Scirica</surname><given-names>BM</given-names></name><name><surname>Emanuelsson</surname><given-names>H</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name><name><surname>Storey</surname><given-names>RF</given-names></name></person-group><article-title>DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 Trial</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>50</volume><fpage>1844</fpage><lpage>1851</lpage><pub-id pub-id-type="pmid">17980250</pub-id></element-citation></ref><ref id="b26"><label>26. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>R</given-names></name><name><surname>Butler</surname><given-names>K</given-names></name></person-group><article-title>AZD6140, the first reversible oral platelet P2Y<sub>12</sub> receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect in healthy subjects</article-title><source>Can J Clin Pharmacol</source><year>2008</year><volume>15</volume><fpage>e426</fpage></element-citation></ref><ref id="b27"><label>27. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>PCJ</given-names></name><name><surname>Leadbeater</surname><given-names>PD</given-names></name><name><surname>Chan</surname><given-names>MV</given-names></name><name><surname>Kirkby</surname><given-names>NS</given-names></name><name><surname>Jakubowski</surname><given-names>JA</given-names></name><name><surname>Mitchell</surname><given-names>JA</given-names></name><name><surname>Warner</surname><given-names>TD</given-names></name></person-group><article-title>In the presence of strong P2Y<sub>12</sub> receptor blockade, aspirin provides little additional inhibition of platelet aggregation</article-title><source>J Thromb Haemost</source><year>2011</year><volume>9</volume><fpage>552</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">21143373</pub-id></element-citation></ref><ref id="b28"><label>28. </label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkby</surname><given-names>NS</given-names></name><name><surname>Leadbeater</surname><given-names>PDM</given-names></name><name><surname>Chan</surname><given-names>MV</given-names></name><name><surname>Nylander</surname><given-names>S</given-names></name><name><surname>Mitchell</surname><given-names>JA</given-names></name><name><surname>Warner</surname><given-names>TD</given-names></name></person-group><article-title>Anti-platelet effects of aspirin vary with level of P2Y<sub>12</sub> receptor blockade supplied by either ticagrelor or prasugrel</article-title><source>J Thromb Haem</source><year>2011</year><volume>9</volume><fpage>2103</fpage><lpage>2105</lpage></element-citation></ref></ref-list></back></article>